VectorY to Participate in Key Sector Conferences in April 2023
Amsterdam, The Netherlands, 5 April 2023 – VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases, today announces presentations during the Cell & Gene meeting on the MED, The Economist's Cell & Gene Therapy Summit and the Huntington's Disease Therapeutics Conference (CHDI) during the month of April.
Cell & Gene meeting on the MED, April 12-14, Barcelona, Spain
Presentation title: Precision targeted therapies for neurodegenerative diseases
Presenter: Barbara Sanders, Chief Technology Officer
Date and time: April 13, 15:15 CET
Panel discussion: Planning for CGT Commercial Readiness: Adaptive Manufacturing Strategy
Panelist: Barbara Sanders, Chief Technology Officer
Date and time: April 13, 16:00 CET
The Economist's Cell & Gene Therapy Summit, April 24-25, Brussels, Belgium
Panel discussion: Investor insights: what’s happening in the market
Panelist: Sander van Deventer, Chief Executive Officer
Date and time: April 25, 10:00 CET
Huntington's Disease Therapeutics Conference, April 24-27, Dubrovnik, Croatia
Oral presentation title: Vectorized antibodies effectively target mutant HTT protein for the treatment of Huntington’s Disease
Presenter: Pavlina Konstantinova, Chief Scientific Officer
Session, date and time: Session III: Novel mechanisms, modalities, and candidates for HD therapeutics on April 26, 16:00 CET
Poster presentation title: Vectorized antibodies effectively target mutant HTT protein for the treatment of Huntington’s Disease
Presenter: Rob Haselberg, Team-Lead Translational Biology, Senior Scientist Biomarkers
Date and time: April 26, 13:00 CET
About VectorY
VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington’s disease. For more information, see www.vectorytx.com.